{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:11:28Z","timestamp":1790266288598,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmorw.2026.100765","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:07:16Z","timestamp":1788350836000},"page":"100765","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world characteristics and invasive disease-free survival of resected patients with HR-positive\/HER2-negative early breast cancer: evidence from German population-based cancer registries"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1083-616X","authenticated-orcid":false,"given":"P.","family":"Grieger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.Y.","family":"Beykloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5425-4600","authenticated-orcid":false,"given":"C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0357-5137","authenticated-orcid":false,"given":"J.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Niklas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Twardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"K\u00f6pf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Reil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Luttmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7115-5160","authenticated-orcid":false,"given":"A.","family":"Nennecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8761-1698","authenticated-orcid":false,"given":"S.-Z.","family":"Kim-Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5840-8274","authenticated-orcid":false,"given":"F.","family":"Oesterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Holleczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pritzkuleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0490-1554","authenticated-orcid":false,"given":"A.","family":"Katalinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5909-9936","authenticated-orcid":false,"given":"A.","family":"Waldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmorw.2026.100765_bib1","series-title":"Krebs in Deutschland f\u00fcr 2019\/2020. 14. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg)","year":"2023"},{"issue":"5","key":"10.1016\/j.esmorw.2026.100765_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.esmorw.2026.100765_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"9793","key":"10.1016\/j.esmorw.2026.100765_bib4","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"issue":"10001","key":"10.1016\/j.esmorw.2026.100765_bib5","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.esmorw.2026.100765_bib6","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100765_bib7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1186\/s12885-019-5710-5","article-title":"Risk of loco-regional recurrence and distant metastases of patients with invasive breast cancer up to ten years after diagnosis: results from a registry-based study from Germany","volume":"19","author":"Holleczek","year":"2019","journal-title":"BMC Cancer"},{"issue":"24","key":"10.1016\/j.esmorw.2026.100765_bib8","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1200\/JCO.20.03613","article-title":"Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmorw.2026.100765_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35817","article-title":"Correlation analysis of invasive disease-free survival and overall survival in a real-world population of patients with HR+\/HER2\u2212 early breast cancer","volume":"131","author":"Graff","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.esmorw.2026.100765_bib10","series-title":"Bekanntmachung: Aktualisierter einheitlicher onkologischer Basisdatensatz der Arbeitsgemeinschaft Deutscher Tumorzentren e.V. (ADT) und der Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (GEKID) Vom 27. M\u00e4rz 2014 BAnz AT","year":"2014"},{"key":"10.1016\/j.esmorw.2026.100765_bib11","series-title":"Gesetz zur Weiterentwicklung der Krebsfr\u00fcherkennung und zur Qualit\u00e4tssicherung durch klinische Krebsregister (Krebsfr\u00fcherkennungs- und -registergesetz \u2013 KFRG), \u00a765c SGB V","year":"2013"},{"key":"10.1016\/j.esmorw.2026.100765_bib32","series-title":"TNM classification of malignant tumours","author":"Brierley","year":"2017"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100765_bib12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.esmorw.2026.100765_bib13","series-title":"R: a language and environment for statistical computing","year":"2026"},{"key":"10.1016\/j.esmorw.2026.100765_bib14","author":"Therneau"},{"key":"10.1016\/j.esmorw.2026.100765_bib15","author":"Kassambara"},{"key":"10.1016\/j.esmorw.2026.100765_bib16","author":"Harrison"},{"key":"10.1016\/j.esmorw.2026.100765_bib17","author":"Gordon"},{"issue":"12","key":"10.1016\/j.esmorw.2026.100765_bib18","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO guidance for reporting oncology real-world evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmorw.2026.100765_bib19","article-title":"Merging of comprehensive data and completeness of information on diagnosis, treatment and progression from several population-based cancer registries in Germany: initial experiences using the example of lung cancer","volume":"21","author":"Waldmann","year":"2025","journal-title":"GMS Med Inform Biom Epidemiol"},{"issue":"8","key":"10.1016\/j.esmorw.2026.100765_bib20","doi-asserted-by":"crossref","first-page":"e1372","DOI":"10.1002\/onco.13813","article-title":"Real-world clinical outcomes in biological subgroups of breast cancer in the hospital district of southwest Finland","volume":"26","author":"Teerenhovi","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.esmorw.2026.100765_bib21","article-title":"Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+\/HER2\u2212 early breast cancer","volume":"81","author":"O\u2019Shaughnessy","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.esmorw.2026.100765_bib22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.breast.2021.08.005","article-title":"Population-based recurrence rates among older women with HR-positive, HER2-negative early breast cancer: clinical risk factors, frailty status, and differences by race","volume":"59","author":"Zhou","year":"2021","journal-title":"Breast"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100765_bib23","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s12282-025-01700-y","article-title":"Risk factors for early recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study in Japan (WJOG15721B)","volume":"32","author":"Watanuki","year":"2025","journal-title":"Breast Cancer"},{"issue":"10","key":"10.1016\/j.esmorw.2026.100765_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105764","article-title":"Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancer","volume":"10","author":"Walbaum","year":"2025","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.esmorw.2026.100765_bib25","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002593","article-title":"Breast-conserving surgery rates in breast cancer patients with different molecular subtypes: an observational study based on surveillance, epidemiology, and end results (SEER) database","volume":"95","author":"Chen","year":"2016","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100765_bib26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10549-022-06561-z","article-title":"Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016","volume":"193","author":"Bowles","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100765_bib28","doi-asserted-by":"crossref","first-page":"252","DOI":"10.36469\/jheor.2025.137277","article-title":"Size and treatment outcomes of HR+, HER2\u2212 early breast cancer population with high risk of recurrence: a real-world cohort study with Danish Breast Cancer Cooperative Group Registry Data","volume":"12","author":"Loponen","year":"2025","journal-title":"J Health Econ Outcomes Res"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100765_bib29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40487-024-00324-0","article-title":"Real-world observational study of incidence and outcomes in an HR+\/HER2\u2212 early breast cancer population with high-risk of recurrence in Finland","volume":"13","author":"Singh","year":"2025","journal-title":"Oncol Ther"},{"issue":"21","key":"10.1016\/j.esmorw.2026.100765_bib30","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.2217\/fon-2022-0310","article-title":"A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer","volume":"18","author":"Sheffield","year":"2022","journal-title":"Future Oncol"},{"issue":"15","key":"10.1016\/j.esmorw.2026.100765_bib31","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.3390\/cancers15153934","article-title":"Population-based clinical cancer registration in Germany","volume":"15","author":"Katalinic","year":"2023","journal-title":"Cancers"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126000846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126000846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:39:57Z","timestamp":1790264397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820126000846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":31,"alternative-id":["S2949820126000846"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100765","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world characteristics and invasive disease-free survival of resected patients with HR-positive\/HER2-negative early breast cancer: evidence from German population-based cancer registries","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100765","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100765"}}